In a reassuring and well-received trading update ahead of FY 2020 results set for July, Aortech have detailed their FY royalty and licensing revenues, cash balance and product developments. After many years in the making, the ElastEon tri-leaflet heart valve now appears to be ready for ‘prime time’. While the acquisition of RUA Medical is completed, we await the name change at Companies House before publishing under RUA Medical PLC.
13 May 2020
Trading update
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Trading update
RUA Life Sciences Plc (RUA:LON) | 11.0 -0.1 (-4.3%) | Mkt Cap: 6.83m
- Published:
13 May 2020 -
Author:
Andy Smith -
Pages:
4
In a reassuring and well-received trading update ahead of FY 2020 results set for July, Aortech have detailed their FY royalty and licensing revenues, cash balance and product developments. After many years in the making, the ElastEon tri-leaflet heart valve now appears to be ready for ‘prime time’. While the acquisition of RUA Medical is completed, we await the name change at Companies House before publishing under RUA Medical PLC.